Novocure files for FDA approval of TTFields for pancreatic cancer
Novocure has filed an application asking the U.S. Food and Drug Administration to approve its Tumor Treating Fields (TTFields) therapy for treating locally advanced…
News
Glioblastoma treatment combo shows promise in pilot study
A combination therapy for glioblastoma showed encouraging early results, with all five patients treated in a pilot study responding to it. Based on the data,…
Stenoparib wins FDA fast track status for advanced ovarian cancer
The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
New gene therapy for multiple myeloma enters clinical trial
The first patient has been dosed in a Phase 1 clinical trial that’s testing a gene therapy for people with recurring or treatment-resistant multiple…
Xspray seeking FDA approval for oral CML treatment XS003
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
Study provides insight into pancreatic cancer development
Glitches in a cellular process that are often seen in neurodegenerative diseases and dementia may also play a role in pancreatic cancer development, a…
Modeyso becomes 1st FDA-approved treatment for rare glioma
Jazz Pharmaceuticals said the U.S. Food and Drug Administration (FDA) granted accelerated approval to the weekly oral therapy dordaviprone, to be marketed under the brand…
‘Off-the-shelf’ NKT cell therapy can overcome ovarian cancer defenses
A cell-based immunotherapy that’s designed to overcome the defense mechanisms that help ovarian cancer evade treatment was highly effective at killing cancer cells in preclinical…
EU expands Sarclisa approval for wider range of myeloma patients
The European Union (EU) expanded its approval of Sarclisa (isatuximab-irfc), making it available to newly diagnosed adults with multiple myeloma who are eligible for…
Blood cancer therapy SGR-2921 discontinued after patient deaths
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
